Minisymposium: Cancer Vaccines and Dendritic Cells

Okt 12
12. Oktober 2019 8:30 Uhr bis 16:00 Uhr
Hotel Novotel Erlangen

Minisymposium: Cancer Vaccines and Dendritic Cells
Saturday 12th October, Hotel Novotel Erlangen, 91052 Erlangen, Germany

8:30 – 8:45 a.m. Welcome
Gerold Schuler

8:45 – 9:15 a.m. Regulation of onco-immune pathways and their modifications by tumor cells
Daniel Speiser

9:15 – 9:45 a.m. Cancer immunosurveillance and preventative cancer vaccines
Olivera J. Finn

9:45 – 10:15 a.m. The challenge of combination immunotherapy for late stage cancer
Cornelius JM Melief

10:15 – 10:45 a.m. Coffee Break

10:45 – 11:15 a.m. On the development of personalized cancer vaccines
Hans-Georg Rammensee

11:15 – 11:45 a.m. Vaccination of cancer patients with Wilms Tumor 1 mRNA: clinical responses, increased survival and correlation with T-cell response
Zwi N. Berneman

11:45 – 12:15 p.m.
mRNA therapeutics: ex-vivo and in vivo modification of dendritic cells
Kris Thielemans

12:15 – 13:15 p.m. Lunch Break

13:15 – 13:45 p.m. Exploiting the mutanome for tumor vaccination
Christoph H. Huber

13:45 – 14:15 p.m. What can we learn about dendritic cells using system approaches?
Joachim Schultze

14:15 – 14:45 p.m. The tumor myeloid microenvironment and its contribution to tumor immunity
Miriam Merad

14.45 – 15.15 p.m. Tumor-resident dendritic cells determine the fate of tumor-specific cytotoxic T cell response
Stefani Spranger

15.15 – 15.30 p.m. Closing Remarks

15.30 – 16.00 p.m. Coffee and Snacks

Zwi N. Berneman
Professor of Hematology, University of Antwerp
Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp
Head, Division of Hematology
Medical Director, Center for Cell Therapy and Regenerative Medicine
Antwerp University Hospital (UZA)

Olivera J. Finn, PhD
Distinguished Professor, Department of Immunology, University of Pittsburgh School of Medicine

Christoph H. Huber, MD
Professor emeritus, Klinik für Hämatologie-Onkologie-Pneumologie, Universitätsmedizin Mainz
Founder of CIMT (, Co-Founder of TRON ( and BioNTech SE (
Board member Cutting Edge Technology Cluster Individualized Immunotherapy (

Prof. Cornelis Melief, MD, PhD
Emeritus professor at Leiden University, Chief Scientific Officer at ISA Pharmaceuticals

Miriam Merad, MD, PhD
Endowed Professor of Cancer Immunology
Director Precision Immunology Institute at Icahn School of Medicine at Mount Sinai (PrIISM) New York

Prof. Dr. Hans-Georg Rammensee
Department of Immunology, University Tübingen

Prof. Dr. Joachim Schultze
Department for Genomics & Immunoregulation, LIMES-Institute, University of Bonn
PRECISE Platform for Single Cell Genomics and Epigenomics, DZNE and University of Bonn

Prof. Daniel Speiser
Department of Oncology, University Hospital and University of Lausanne

Stefani Spranger, PhD
Assistant Professor of Biology (MIT)
Koch Institute for Integrative Cancer Research at MIT
Associate Member Ragon Institute of MGH, MIT and Harvard

Prof. Kris Thielemans
Vrije University of Brussel